Abstract
Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). This endothelium-derived NO is a protective molecule with antihypertensive, antithrombotic and anti-atherosclerotic properties. Cardiovascular risk factors such as hypertension, hypercholesterolemia, cigarette smoking and diabetes mellitus induce oxidative stress mostly by stimulation of the NADPH oxidase. Overproduction of reactive oxygen species leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide- producing enzyme. Consequently, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to cardiovascular pathology. Therefore, pharmacological approaches that prevent eNOS uncoupling are of therapeutic interest. Among the drugs currently in clinical use, the renin inhibitor aliskiren, angiotensin-converting enzyme inhibitors, AT1 receptor blockers, the selective aldosterone antagonist eplerenone, statins, nebivolol and pentaerithrityl tetranitrate have been shown to have the potential to prevent or reverse eNOS uncoupling under experimental conditions. Resveratrol, BH4, sepiapterin, folic acid and AVE3085 have also been shown to recouple eNOS and improve endothelial function. The long-term benefit of these compounds, however, is still controversial.
Keywords: Nitric oxide, endothelial NO synthase, eNOS uncoupling, NADPH oxidase; oxidative stress.
Current Pharmaceutical Design
Title:Pharmacological Prevention of eNOS Uncoupling
Volume: 20 Issue: 22
Author(s): Huige Li and Ulrich Forstermann
Affiliation:
Keywords: Nitric oxide, endothelial NO synthase, eNOS uncoupling, NADPH oxidase; oxidative stress.
Abstract: Under physiological conditions, nitric oxide (NO) is produced in the vasculature mainly by the endothelial NO synthase (eNOS). This endothelium-derived NO is a protective molecule with antihypertensive, antithrombotic and anti-atherosclerotic properties. Cardiovascular risk factors such as hypertension, hypercholesterolemia, cigarette smoking and diabetes mellitus induce oxidative stress mostly by stimulation of the NADPH oxidase. Overproduction of reactive oxygen species leads to oxidation of tetrahydrobiopterin (BH4), the essential cofactor of eNOS. In BH4 deficiency, oxygen reduction uncouples from NO synthesis, thereby converting eNOS to a superoxide- producing enzyme. Consequently, NO production is reduced and the pre-existing oxidative stress is enhanced, which contribute significantly to cardiovascular pathology. Therefore, pharmacological approaches that prevent eNOS uncoupling are of therapeutic interest. Among the drugs currently in clinical use, the renin inhibitor aliskiren, angiotensin-converting enzyme inhibitors, AT1 receptor blockers, the selective aldosterone antagonist eplerenone, statins, nebivolol and pentaerithrityl tetranitrate have been shown to have the potential to prevent or reverse eNOS uncoupling under experimental conditions. Resveratrol, BH4, sepiapterin, folic acid and AVE3085 have also been shown to recouple eNOS and improve endothelial function. The long-term benefit of these compounds, however, is still controversial.
Export Options
About this article
Cite this article as:
Li Huige and Forstermann Ulrich, Pharmacological Prevention of eNOS Uncoupling, Current Pharmaceutical Design 2014; 20 (22) . https://dx.doi.org/10.2174/13816128113196660749
DOI https://dx.doi.org/10.2174/13816128113196660749 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin
Current Pharmaceutical Design Correlations Between Cerebellar and Brain Volumes, Cognitive Impairments, ApoE Levels, and APOE Genotypes in Patients with AD and MCI
Current Alzheimer Research Nuclear Receptors CAR and PXR in Metabolism and Elimination of Drugs
Current Pharmacogenomics New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry From Peptides to Small Molecules: An Intriguing but Intricated Way to New Drugs
Current Medicinal Chemistry Bacterial Protein Toxins: Current and Potential Clinical Use
Current Medicinal Chemistry Atrial Fibrillation During or After TAVI: Incidence, Implications and Therapeutical Considerations
Current Pharmaceutical Design Editorial [Hot topic: Predictions and Determinations of Protein and Peptide Structures (Guest Editor: Guo-Ping Zhou)]
Protein & Peptide Letters Medicinal Chemistry of Indolylglyoxylamide TSPO High Affinity Ligands with Anxiolytic-Like Effects
Current Topics in Medicinal Chemistry Hepatic Cytochrome P450 Regulation in Disease States
Current Drug Metabolism Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Chemical Changes in Dairy Products Resulting from Cholesterol Removal Using Beta Cyclodextrins
Current Nutrition & Food Science Therapeutic Role of Methanolic Extract of Ocimum basilicum L. Seeds and its Isolated Compound as Potent Antidiabetic and Antihyperlipidemic Agents
The Natural Products Journal The Malignant Obesity Hypoventilation Syndrome (MOHS)
Current Respiratory Medicine Reviews Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology Nanostructures for Treating Musculoskeletal Conditions
Current Bioactive Compounds Effect of Nanogel Structure and Reaction Parameters on Activity of Immobilized Glucose Oxidase
Current Catalysis Can Functionally Mature Islet β-Cells be Derived from Pluripotent Stem Cells? A Step Towards Ready-To-Use β-Cells in Type 1 Diabetes
Current Stem Cell Research & Therapy Antihyperglycemic and Antidyslipidemic Activities of the <i>Aqueous Salvia hispanica</i> Extract in Diabetic Rat
Cardiovascular & Hematological Agents in Medicinal Chemistry Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued)